Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practice
Many relapsed lymphoma patients excluded from clinical trials actually survive as well as those accepted, suggesting some trial rules may be too strict.
This multi-center Australian study demonstrates that more than half of real-world relapsed DLBCL patients are excluded from any of seven registrational trials due to heterogeneous and restrictive eligibility criteria, with eligibility ranging from just 4% to 22% across trials. Importantly, overall survival did not differ between patients ineligible and those eligible for trials, raising questions about whether current exclusion criteria are appropriately risk-stratified.
What the study was
- Study design
- Retrospective observational cohort study (Australian lymphoma registry, multi-center)
- Population
- Real-world cohort of 180 relapsed/refractory DLBCL patients with 320 relapses, treated in Australia; criteria from 7 registrational rDLBCL trials applied retrospectively
- Sample size
- 180
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- British Journal of Haematology
Why it surfaced
Clinically important finding that 52% of real-world rDLBCL patients are excluded from trials; high policy relevance for trial design reform in hematologic oncology. Eligible-ineligible survival equivalence challenges restrictive criteria.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.